Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa

Libyan Journal of Medicine

Volumn 6, Issue 1, 2011, Pages 1-8

  Askoura, Momen ^a   Mottawea, Walid ^a   Abujamel, Turki ^a   Taher, Ibrahim ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antibiotic resistance; Efflux pumps; Pseudomonas aeruginosa

Indexed keywords

2 NAPHTHYLAMINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; D 13 9001; EFFLUX PUMP INHIBITOR; MC 04 124; PHENYLALANINE ARGINYL BETA NAPHTHYLAMIDE; PROTEIN MEXAB; PROTEIN MEXCD; PROTEIN MEXEF; PROTEIN MEXGHI; PROTEIN MEXR; PROTEIN MEXXY; PROTEIN OPMD; PROTEIN OPRD; PROTEIN OPRJ; PROTEIN OPRM; PROTEIN OPRN; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GENETICS; BIOFILM; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSPORT; GENE EXPRESSION REGULATION; GENETIC ORGANIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MULTIDRUG RESISTANCE; NONHUMAN; OPERON; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; STRUCTURE ACTIVITY RELATION;

EID: 80053584182     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v6i0.5870     Document Type: Article

References (59)

1. Farhat U, Salman A, Jawad A. Antimicrobial susceptibility and ESBL prevalence in Pseudomonas aeruginosa isolated from burn patients in the North West of Pakistan. Burns. 2009; 35: 1020-5.
2. Jeff GL, Mathias K, Candice S, Chelsa J, Gabriel M, Alyssa S, et al. Flagellum-mediated biofilm defense mechanisms of Pseudomonas aeruginosa against host-derived lactoferrin. Infect Immun. 2009; 77: 4559-66.
3. McGowan JE Jr. Resistance in non-fermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control. 2006; 34: 29-37.
4. Hancock RE, Speert DP. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Updat. 2000; 3: 247-55.
5. Falagas ME, Bliziotis IA. Pandrug-resistant gram negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007; 29: 630-6.
6. Gooderham WJ, Hancock REW. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev. 2009; 33: 279-94.
7. Neda G, Scott A, Andrew P, Nader P. Detection of point mutations associated with antibiotic resistance in Pseudomonas aeruginosa. Int J Antimicrob Agents. 2009; 34: 414-8.
8. Page MG, Heim J. Prospects for the next anti Pseudomonas drug. Curr Opin in Pharmacol. 2009; 9: 558-65.
9. Vidal-Aroca F, Meng A, Minz T, Page MG, Dreier J. Use of resazurin to detect mefloquine as an efflux-pump inhibitor in Pseudomonas aeruginosa and Escherichia coli. J Microbiol Methods. 2009; 79: 232-7.
10. Dreier J. Active drug efflux in bacteria. In: Bonomo RA, Tolmasky M, editors. Enzyme-mediated resistance to antibiotics. Washington, DC: ASM Press; 2007. p. 235-64.
11. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002; 34: 634-40.
12. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbio Rev. 2006; 19: 382-402.
13. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeuroginosa and related bacteria: unanswered questions. Genet Mol Res. 2003; 2: 48-62.
14. Misra R, Bavro VN. Assembly and transport mechanism of tripartite drug efflux systems. Biochimica et Biophysica Acta. 2009; 1794: 817-25.
15. Tanya S, Daniel Y. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol. 2009; 58: 1133-48.
16. George GZ, Daryl JH, Kristen S, James AK. Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa. Int J Antimicrob Agents. 2004; 24: 529-35.
17. Yoshida K, Nakayama K, Yokomizo Y, Ohtsuka M, Takemura M, Hoshino K, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa, Part 6: exploration of aromatic substituents. Bioorg Med Chem. 2006; 14: 8506-18.
18. Hirakata Y, Kondoc A, Hoshino K, Yano H, Arai K, Hirotani A, et al. Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2009; 34: 343-6.
19. Mima T, Sekiya H, Mizushima T, Kuroda T, Tsuchiya T. Gene cloning and properties of the RND-type multidrug efflux pumps MexPQ-OpmE and MexMN-OprM from Pseudomonas aeruginosa. Microbiol Immunol. 2005; 49: 999-1002.
20. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol. 2001; 3: 255-63.
21. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature. 2006; 443: 173-9.
22. Higgins MK, Bokma E, Koronakis E, Hughes C, Koronakis V. Structure of the periplasmic component of a bacterial drug efflux pump. Proc Natl Acad Sci. 2004; 101: 9994-9.
23. Eda S, Maseda H, Nakae T. An elegant means of self-protection in gram-negative bacteria by recognizing and extruding xenobiotics from the periplasmic space. J Biol Chem. 2003; 278: 2085-8.
24. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2000; 44: 710-2.
25. Papadopoulos CJ, Christine FC, Barbara JC, Riley TV. Role of the MexAB-OprM efflux pump of Pseudomonas aeruginosa in tolerance to tea tree (Melaleuca alternifolia) oil and its monoterpene components terpinen-4-ol, 1,8-cineole, and a-terpineol. Appl Environmen Microbiol. 2008; 74: 1932-5.
26. Rieg S, Huth A, Kalbacher H, Kern WV. Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps. Int J Antimicrob Agents. 2009; 33: 174-6.
27. Jeannot K, Elsen S, Köhler T, Attree I, van Delden C, Plésiat P. Resistance and virulence of Pseudomonas aeruginosa clinical strains overproducing the MexCD-OprJ efflux pump. Antimicrob Agents Chemoth. 2008; 52: 2455-62.
28. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001; 9: 34-9.
29. Zhang L, Mah TF. Involvement of a novel efflux system in biofilm-specific resistance to antibiotics. J Bacteriol. 2008; 190: 4447-52.
30. Aendekerk S, Ghysels B, Cornelis P, Baysse C. Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium. Microbiology. 2002; 148: 2371-81.
31. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCDOprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemoth. 2000; 44: 3322-7.
32. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of Triclosan. J Bacteriol. 2002; 184: 5036-44.
33. Hao C, Jie H, Peng RC, Lefu L, Zigang L, Leslie MH, et al. The Pseudomonas aeruginosa multidrug efflux regulator MexR uses an oxidation-sensing mechanism. PNAS. 2008; 105: 13586-91.
34. Sugimura M, Maseda H, Hanaki H, Nakae T. Macrolide antibiotic-mediated down regulation of MexAB-OprM efflux pump expression in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008; 52: 4141-4.
35. Adewoye L, Sutherland A, Srikumar R, Poole K. The MexR repressor of the mexAB-oprM multidrug efflux operon in Pseudomonas aeruginosa: characterization of mutations compromising activity. J Bacteriol. 2002; 184: 4308-12.
36. Eisaku Y, Shima E, Sayaka K. Functional interaction sites of OprM with MexAB in the Pseudomonas aeruginosa multidrug efflux pump. FEMS Microbiology Letters. 2009; 299: 200-4.
37. Pagès J-M, Amaral L. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of gram-negative bacteria. Biochimica et Biophysica Acta. 2009; 1794: 826-33.
38. Tohidpour A, Peerayeh SN, Mehrabadi JF, Yazdi HR. Determination of the efflux pump mediated resistance prevalence in Pseudomonas aeruginosa, using an efflux pump inhibitor. Curr Microbiol. 2009; 59: 352-5.
39. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès JM. Antibiotic efflux pumps in gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemoth. 2007; 59: 1223-9.
40. Poole K, Lomovskaya O. Can efflux inhibitors really counter resistance? Infect Disease. 2006; 3: 145-52.
41. Mahamoud A, Chevalier J, Davin-Regli A. Quinolone derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes. Curr Drug Targets. 2006; 7: 843-7.
42. Ghisalberti D, Mahamoud A, Baitiche M. Chloroquinolines block antibiotic efflux pump in resistant Enterobacter aerogenes isolates. Int J Antimicrob Agents. 2006; 27: 565-9.
43. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother. 2001; 45: 105-16.
44. Renau TE, Léger R, Yen R, She MW, Flamme EM, Sangalang J, et al. Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett. 2002; 12: 763-6.
45. Renau TE, Léger R, Filonova L, Flamme EM, Wang M, Yen R, et al. Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg Med Chem Lett. 2003; 13: 2755-8.
46. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic - a vision for applied use. Biochem Pharmacol. 2006; 71: 910-8.
47. Watkins WJ, Landaverry Y, Léger R, Litman R, Renau TE, Williams N, et al. The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors. Bioorg Med Chem Lett. 2003; 13: 4241-4.
48. Yoshida K, Nakayama K, Kuru N, Kobayashi S, Ohtsuka M, Takemura M, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa, Part 5: carbon-substituted analogues at the C-2 position. Bioorg Med Chem. 2006; 14: 1993-2004.
49. Yoshida KI, Nakayama K, Ohtsuka M, Kuru N, Yokomizo Y, Sakamoto A, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem. 2007; 15: 7087-97.
50. Kriengkauykiat J, Porter E, Lomovskaya O. Use of an efflux pump inhibitor to determine the prevalence of efflux pumpmediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005; 49: 565-70.
51. Benedict RG, Langlykke AF. Antibiotic activity of bacillus polymyxa. J Bacteriol. 1947; 54: 24-5.
52. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40: 1333-41.
53. Li JK, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6: 589-601.
54. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006; 12: 315-21.
55. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother. 2003; 52: 987-92.
56. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with gram-negative bacterial infections. Antimicrob Agents Chemother. 2009; 53: 3430-6.
57. Widmer AF, Wenzel RP, Trilla A, Bale MJ, Jones RN, Doebbeling BN. Outbreak of Pseudomonas aeruginosa infections in a surgical intensive care unit: probable transmission via hands of a health care worker. Clin Infect Dis. 1993; 16: 372-6.
58. Moolenaar RL, Crutcher JM, San Joaquin VH, Sewell LV, Hutwagner LC, Carson LA, et al. A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission? Infect Control Hosp Epidemiol. 2000; 21: 80-5.
59. Lomovskaya O, Zgurskaya HI, Totrov M, Watkins WJ. Waltzing transporters and 'the dance macabre' between humans and bacteria. Nat Rev. Drug Discov. 2007; 6: 56-65.